FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3004779969> ?p ?o ?g. }

• W3004779969 endingPage "729" @default.
• W3004779969 startingPage "715" @default.
• W3004779969 abstract "The formation and accumulation of amyloid aggregates are the phenomena that accompany amyloidoses, which are currently untreatable and include Alzheimer’s and Parkinson’s diseases, diabetes mellitus, non-neuropathic lysozyme systemic amyloidosis, and others. One of the very promising therapeutic approaches seems to be an inhibition of amyloid formation and/or clearance of amyloid aggregates. Small molecules have a great potential to interfere with amyloid fibrillation of peptides and polypeptides, which can be improved by connection of cyclic structures into single multicyclic molecules and their dimerization. In our study, we focused on heterodimers consisting of 7-methoxytacrine (7-MEOTA) and 2-aminobenzothiazole (BTZ) parent molecules connected by an aliphatic linker. Using in vitro and in silico methods, we investigated the ability of studied compounds to inhibit the amyloid aggregation of hen egg white lysozyme. Heterodimerization led to significant improvement of inhibitory activity compared to that of the parent molecules. The efficiency of the heterodimers varied; the most effective inhibitor contained the longest linker, eight carbons long. We suggest that binding of a heterodimer to a lysozyme blocks the interaction between the β-domain and C-helix region essential for the formation of amyloid cross-β structure. Elongation of the linker ultimately enhances the compound’s ability to prevent this interaction by allowing the BTZ part of the heterodimer to bind more effectively, increasing the compound’s binding affinity, and also by greater steric obstruction. This study represents an important contribution to the recent rational design of potential lead small molecules with anti-amyloid properties, and the heterodimers studied are prospective candidates for the treatment of systemic lysozyme amyloidosis and other amyloid-related diseases." @default.
• W3004779969 created "2020-02-14" @default.
• W3004779969 creator A5002573915 @default.
• W3004779969 creator A5004042314 @default.
• W3004779969 creator A5013987157 @default.
• W3004779969 creator A5014860684 @default.
• W3004779969 creator A5019636088 @default.
• W3004779969 creator A5020199378 @default.
• W3004779969 creator A5021552481 @default.
• W3004779969 creator A5076051295 @default.
• W3004779969 creator A5087297069 @default.
• W3004779969 creator A5087870164 @default.
• W3004779969 date "2020-02-03" @default.
• W3004779969 modified "2023-10-17" @default.
• W3004779969 title "7-Methoxytacrine and 2-Aminobenzothiazole Heterodimers: Structure–Mechanism Relationship of Amyloid Inhibitors Based on Rational Design" @default.
• W3004779969 cites W1031578623 @default.
• W3004779969 cites W1418227753 @default.
• W3004779969 cites W1589250757 @default.
• W3004779969 cites W1968788242 @default.
• W3004779969 cites W1973897761 @default.
• W3004779969 cites W1975580333 @default.
• W3004779969 cites W1976499671 @default.
• W3004779969 cites W1979836009 @default.
• W3004779969 cites W1981021420 @default.
• W3004779969 cites W1987066756 @default.
• W3004779969 cites W1987734353 @default.
• W3004779969 cites W1988583668 @default.
• W3004779969 cites W1988745994 @default.
• W3004779969 cites W1993221555 @default.
• W3004779969 cites W1996524234 @default.
• W3004779969 cites W1999019541 @default.
• W3004779969 cites W2001752726 @default.
• W3004779969 cites W2003833259 @default.
• W3004779969 cites W2006360252 @default.
• W3004779969 cites W2008708467 @default.
• W3004779969 cites W2011290762 @default.
• W3004779969 cites W2013176372 @default.
• W3004779969 cites W2015688756 @default.
• W3004779969 cites W2018783217 @default.
• W3004779969 cites W2021229113 @default.
• W3004779969 cites W2028181978 @default.
• W3004779969 cites W2037535298 @default.
• W3004779969 cites W2044632501 @default.
• W3004779969 cites W2045182799 @default.
• W3004779969 cites W2045683699 @default.
• W3004779969 cites W2046697874 @default.
• W3004779969 cites W2047399603 @default.
• W3004779969 cites W2047730466 @default.
• W3004779969 cites W2056324592 @default.
• W3004779969 cites W2057477511 @default.
• W3004779969 cites W2061151008 @default.
• W3004779969 cites W2063096624 @default.
• W3004779969 cites W2067174909 @default.
• W3004779969 cites W2074473216 @default.
• W3004779969 cites W2077059634 @default.
• W3004779969 cites W2081693079 @default.
• W3004779969 cites W2087277033 @default.
• W3004779969 cites W2088791119 @default.
• W3004779969 cites W2094499026 @default.
• W3004779969 cites W2122850286 @default.
• W3004779969 cites W2128572087 @default.
• W3004779969 cites W2134967712 @default.
• W3004779969 cites W2144288821 @default.
• W3004779969 cites W2147993766 @default.
• W3004779969 cites W2156635425 @default.
• W3004779969 cites W2158576753 @default.
• W3004779969 cites W2253226032 @default.
• W3004779969 cites W2325034207 @default.
• W3004779969 cites W2327040563 @default.
• W3004779969 cites W2327581403 @default.
• W3004779969 cites W2330799739 @default.
• W3004779969 cites W2479741218 @default.
• W3004779969 cites W2493514632 @default.
• W3004779969 cites W2499497885 @default.
• W3004779969 cites W2549889200 @default.
• W3004779969 cites W2587284634 @default.
• W3004779969 cites W2731784911 @default.
• W3004779969 cites W2783255301 @default.
• W3004779969 cites W2789819212 @default.
• W3004779969 cites W2790953989 @default.
• W3004779969 cites W2794648115 @default.
• W3004779969 cites W2803357784 @default.
• W3004779969 cites W2884887336 @default.
• W3004779969 doi "https://doi.org/10.1021/acschemneuro.9b00419" @default.
• W3004779969 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32011847" @default.
• W3004779969 hasPublicationYear "2020" @default.
• W3004779969 type Work @default.
• W3004779969 sameAs 3004779969 @default.
• W3004779969 citedByCount "10" @default.
• W3004779969 countsByYear W30047799692020 @default.
• W3004779969 countsByYear W30047799692021 @default.
• W3004779969 countsByYear W30047799692022 @default.
• W3004779969 countsByYear W30047799692023 @default.
• W3004779969 crossrefType "journal-article" @default.
• W3004779969 hasAuthorship W3004779969A5002573915 @default.
• W3004779969 hasAuthorship W3004779969A5004042314 @default.
• W3004779969 hasAuthorship W3004779969A5013987157 @default.
• W3004779969 hasAuthorship W3004779969A5014860684 @default.

• next